Heron Therapeutics, Inc. (HRTX)

NASDAQ: HRTX · USD

$0.31

+0.01 (+2.8%)· Recorded snapshot

Market cap	58.8M
Revenue (ttm)	151.2M
Net income (ttm)	-34M
EPS (ttm)	-$0.18
Shares out	189.9M
Volume	653,695
Beta	1.62

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 151.2M
Net income (ttm): -34M
EPS (ttm): -$0.18
Market cap: 58.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-4.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All HRTX indicators

Market & fundamental data

Available fields

213

Groups with data

Currency

USD

Showing 213 of 213 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000818033
Company name	Heron Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	427746102
Earnings date	2026-11-09
Earnings time	bmo
Employees	128
Employees change	6
Employees growth	4.92%
Enterprise value	$164.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1983
In index	RUSSELL2000
Industry	Biotechnology
IPO date	1987-08-26
Is primary listing	Yes
Is SPAC	No
ISIN number	US4277461020
Last 10-K release date	2026-02-26
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split date	2014-01-13
Last stock split type	Reverse
Market cap	$58.8M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$0.31
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	HRTX
U.S. state	North Carolina
Website	https://www.herontx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-59.47%
EV/Sales	1.09x
FCF / EV yield	-7.39%
FCF yield	-20.77%
Forward EV/Sales	2.16x
Forward P/S	0.77x
P/B ratio	9.75x
P/S ratio	0.39x
Price / tangible book value	9.98x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-7.19%
EBITDA margin	-5.78%
Gross margin	61.93%
Operating margin	-7.19%
Pretax margin	-22.52%
Profit margin	-22.52%
Profit per employee	$-266,008
Revenue per employee	$1.2M
ROA	-2.8%
ROA (5Y)	-21.48%
ROCE	-6.79%
ROIC	-4.46%
SBC / revenue	7.4%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Gross profit growth	-5.27%
Gross profit growth (Q)	-4.17%
Net income growth years	0
Revenue growth	0.99%
Revenue growth (Q)	1.25%
Revenue growth (QoQ)	8.51%
Revenue growth 3Y	8.62%
Revenue growth 5Y	12.73%
Revenue growth quarters	1
Revenue growth years	4

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-529,000
Depreciation and amortization	$2.1M
EBIT	$-10.9M
EBITDA	$-8.7M
EPS	$-0.18
FCF per share	$-0.06
Financing cash flow	$13.6M
Free cash flow	$-12.1M
Free cash flow minus SBC	$-23.3M
Gross profit	$93.6M
Investing cash flow	$2.2M
Net borrowing	$-12.8M
Net cash flow	$4.2M
Net income	$-34M
Operating cash flow minus SBC	$-22.8M
Operating income	$-10.9M
Revenue	$151.2M
Stock-based compensation	$11.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-9.21
Book value per share	$0.03
Debt / equity	21.48
Interest coverage	-0.76
Long-term assets	$22.4M
Long-term liabilities	$153.2M
Net cash (debt)	$-105.7M
Net cash / market cap	-180.86%
Net debt / equity	15.3
Piotroski F-Score	2
Property, plant and equipment	$17.4M
Shareholders' equity	$6.9M
Tangible book value	$5.9M
Tangible book value per share	$0.03
Total assets	$252.3M
Total cash	$42.7M
Total debt	$148.4M
Total liabilities	$245.4M
WACC	9.15%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.62
Current assets	$229.8M
Current liabilities	$92.1M
Current ratio	2.49
Inventory turnover	0.7
Net working capital	$95.2M
Quick ratio	1.44
Working capital	$137.7M
Working capital turnover	3.36

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-20.47%
Dividend yield	0%
Shareholder yield	-20.47%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-98.04%
10Y return CAGR	-32.53%
10Y total return	-98.04%
150-day SMA	$0.56
15Y price change	-94.23%
15Y return CAGR	-17.31%
15Y total return	-94.23%
1D price change	2.75%
1M price change	2.04%
1M total return	2.04%
1W price change	-15.32%
1W total return	-15.32%
1Y price change	-74.56%
1Y return CAGR	-74.58%
1Y total return	-74.56%
20-day SMA	$0.35
200-day SMA	$0.71
20Y price change	-99.67%
20Y return CAGR	-24.83%
20Y total return	-99.67%
3M price change	-34.63%
3M total return	-34.63%
3Y price change	-52.11%
3Y return CAGR	-21.76%
3Y total return	-52.11%
50-day SMA	$0.33
50-day SMA vs 200-day SMA	50under200
52-week high	$1.58
52-week high date	2026-01-09
52-week low	$0.26
52-week low date	2026-09-21
5Y price change	-97.23%
5Y return CAGR	-51.18%
5Y total return	-97.23%
6M price change	-74.77%
6M total return	-74.77%
All-time high	$1,290.00
All-time high date	1992-01-13
All-time low	$0.26
All-time low date	2026-09-21
Average true range (ATR)	$0.03
Average volume	2.3M
Beta (1Y)	3.08
Beta (2Y)	1.59
Beta (5Y)	1.62
Change from 52-week high	-80.33%
Change from 52-week low	18.7%
Change from all-time high	-99.98%
Change from all-time low	15.02%
Change from open	3.47%
Day's gap	-0.7%
Dollar volume	$202,515
High price	$0.31
Low price	$0.30
Monthly RSI	34.82
Open price	$0.30
Position in 52-week range	98.21%
Premarket change	2.49%
Premarket close	$0.30
Premarket price	$0.31
Premarket volume	263
Previous close	$0.30
Price vs 150-day SMA	-46.48%
Price vs 20-day SMA	-14.42%
Price vs 200-day SMA	-57.88%
Price vs 50-day SMA	-8.73%
Relative volume	0.29
RSI	40.84
Sharpe ratio	-1.02
Sharpe ratio (3Y)	0.21
Sharpe ratio (5Y)	-0.32
Sortino ratio	-1.18
Sortino ratio (3Y)	0.37
Sortino ratio (5Y)	-0.39
Volume	653.7K
Weekly RSI	33.87
YTD price change	-76.91%
YTD total return	-76.91%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	146.5M
Float percentage	77.17%
Shares change (QoQ)	0.36%
Shares change (YoY)	20.47%
Shares held by insiders	1.01%
Shares held by institutions	48.02%
Shares outstanding	189.9M
Short % of float	31.41%
Short % of shares	24.24%
Short ratio	21.3 days

Deeper analysis on HRTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this HRTX report

Is a complete HRTX research report available?

No complete published report is available for Heron Therapeutics, Inc. (HRTX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Heron Therapeutics, Inc. (HRTX)

Price

Financial snapshot

Fair-value bridge

Latest news · HRTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All HRTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on HRTX

Frequently asked questions